{"id":"glucagon-12-5ng-kg-min","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a peptide hormone that activates G-protein coupled glucagon receptors, primarily on hepatocytes, triggering intracellular signaling cascades that mobilize stored glycogen and promote glucose synthesis. This results in rapid elevation of blood glucose, making it effective for acute hypoglycemia reversal. The dose specified (12.5 ng/kg/min) suggests continuous intravenous infusion, likely for severe or refractory hypoglycemia management in a clinical setting.","oneSentence":"Glucagon binds to glucagon receptors on hepatic and other cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:18.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute hypoglycemia (severe or refractory)"},{"name":"Hypoglycemia in critical care settings"}]},"trialDetails":[{"nctId":"NCT04307797","phase":"PHASE4","title":"Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2022-01-18","conditions":"Type 2 Diabetes, Obesity","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Glucagon 12.5ng/kg/min","genericName":"Glucagon 12.5ng/kg/min","companyName":"Cambridge University Hospitals NHS Foundation Trust","companyId":"cambridge-university-hospitals-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucagon binds to glucagon receptors on hepatic and other cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Acute hypoglycemia (severe or refractory), Hypoglycemia in critical care settings.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}